News
In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...
In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an immunotherapy drug) plus gemcitabine and cisplatin (GemCis, chemotherapy drugs) as the ...
In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...
The latest advancements in upper gastrointestinal (GI) cancer treatment include early detection tools, immunotherapy, ...
The Phase II trial will compare progression-free survival in lung cancer patients treated according to their molecular subtypes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results